Share on StockTwits

Investment analysts at Cowen and Company started coverage on shares of Quotient (NASDAQ:QTNT) in a note issued to investors on Wednesday. The firm set an “outperform” rating and a $12.00 price target on the stock. Cowen and Company’s target price indicates a potential upside of 81.82% from the company’s current price.

Separately, analysts at Robert W. Baird initiated coverage on shares of Quotient in a research note on Tuesday. They set an “outperform” rating and a $12.00 price target on the stock.

Shares of Quotient (NASDAQ:QTNT) opened at 6.60 on Wednesday. Quotient has a one year low of $6.34 and a one year high of $7.90. The stock has a 50-day moving average of $6.99 and a 200-day moving average of $6.99. The company’s market cap is $94.9 million.

Quotient Limited is a commercial-stage diagnostics company. The Company is engaged in reducing healthcare costs and improving patient care through the development and commercialization of tests for blood grouping and serological disease screening, referred to as transfusion diagnostics.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.